A Study of M701 (EpCAM and CD3) in Malignant Ascites
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple
ascending doses of M701 administered intraperitoneally to patients with malignant ascites
caused by advanced solid tumors.